Following the successful transition of a multi-brand tracker from an incumbent provider, Research Partnership’s client wanted to enhance the power of their ATU for their entire haematology portfolio. In addition to understanding their market share, they were looking to move towards a brand equity-based customer engagement model in order to address their brand objectives and deliver more actionable direction for future marketing activity for the brand teams.
Research Partnership, an Inizio Advisory company, conducted over 200 online interviews with physicians across Europe to understand:
To provide a more holistic understanding of brand equity and a forward indication of potential market share, Research Partnership used their advanced analytics solution, Equity AI.
Equity AI is a competitive behavioral economics model, which links the impact of messaging and a range of other marketing elements to brand equity to provide more accurate and predictive insight into how and where to grow future market share opportunity. It takes into consideration a more encompassing range of brand touchpoints, both the rational (tangible) and emotional (intangible), that drive brand loyalty to calculate ‘brand stock’ and overall preference within the minds of customers.
By using their Equity AI solution to enhance the power of the ATU study, now a brand equity study, Research Partneship was able to compare brand equity and dynamic share to identify opportunities and threats to each of their clients’ brands. Their advanced analytics team then utilised AI and predictive modelling to develop an interactive simulator that mapped out loyalty influences and where to focus future marketing efforts to drive share. The programme was able to show the potential changes in brand equity if ratings of certain attributes changed, enabling their client to determine how addressing the different “levers” impacted brand equity and focus on the areas that would make a real difference to their brand performance.
Jump to a slide with the slide dots.
Our client was new to the complement system space and was preparing to launch an oral, first-in-class medication in a rare blood disease.
Read moreA top 10 pharma company wanted dermatologists to own the conversation on PsA, and become confident in diagnosing the disease.
Read moreA top 10 global pharma company wanted to challenge the status quo when it came to planning and prioritizing congresses.
Read more